|
Getting your Trinity Audio player ready...
|
The medical device sector in the healthcare industry has rapidly advanced in recent years due to its inherent innovation, and Catheter Precision Inc. (NYSE American: VTAK) stands out as a notable player. The company is renowned for its two key products: VIVO™, aiding in ventricular arrhythmia source detection pre-procedure, and LockeT, a closure retention device.
Catheter Precision Inc. (NYSE American: VTAK) recently reported robust initial order momentum for LockeT in Q2 2024 and positive traction for VIVO’s™ initial orders in the latter half of 2024. This development marks a significant milestone, with additional considerations to explore. The distributor validation for LockeT has exceeded projections, instilling notable confidence as the CE Mark launch approaches. See The Complete Report Now.
Management is also forecasting a $10 million run rate by the end of the year, additionally due to the expansion in sales, management anticipates that esteemed academic hospitals will soon be within reach. Moreover, Catheter Precision anticipates favorable feedback on the product’s merits from prestigious global institutions within the next two quarters. The company highlights that sales growth in H2 2024 will hinge significantly on VIVO’s™‘s commercialization progress in new markets.
Related posts:
Stocks in the News: “Key Developments to Watch This Week: CLNV, INBS, VTAK, HALB, SNNC
Stock in the News in Focus: KAVL, INBS, CLNV, PRSNF / PRSN.V, VTAK
“Market Movers: Top Stocks Making Headlines This Week” – KAVL, INBS, VTAK, CLNV
Healthcare Undervalued Opportunities Poised for Growth: DYAI, INBS, VTAK, RSCI, VERO, MRVI
Catheter Precision (NYSE American: VTAK) Shows Fiscal Strength, Solid Growth and Strategic Moves; Bullish Momentum Seen in Stock Price